The BRCA1 gene was previously found to inhibit the transcriptional activity of the estrogen receptor [ER-a] in human breast and prostate cancer cell lines. In this study, we found that breast cancer-associated mutations of BRCA1 abolish or reduce its ability to inhibit ER-a activity and that domains within the amino-and carboxyltermini of the BRCA1 protein are required for the inhibition. BRCA1 inhibition of ER-a activity was demonstrated under conditions in which a BRCA1 transgene was transiently or stably over-expressed in cell lines with endogenous wild-type BRCA1 and in a breast cancer cell line that lacks endogenous functional BRCA1 (HCC1937). In addition, BRCA1 blocked the expression of two endogenous estrogen-regulated gene products in human breast cancer cells: pS2 and cathepsin D. The BRCA1 protein was found to associate with ER-a in vivo and to bind to ER-a in vitro, by an estrogen-independent interaction that mapped to the amino-terminal region of BRCA1 (ca. amino acid 1-300) and the conserved carboxyl-terminal activation function [AF-2] domain of ER-a. Furthermore, several truncated BRCA1 proteins containing the amino-terminal ER-a binding region blocked the ability of the full-length BRCA1 protein to inhibit ER-a activity. Our ®ndings suggest that the aminoterminus of BRCA1 interacts with ER-a, while the carboxyl-terminus of BRCA1 may function as a transcriptional repression domain. Oncogene (2001) 20, 77 ± 87.
Introduction
Hereditary mutations of the breast cancer susceptibility gene BRCA1 cause an increased risk for breast, ovarian, and possibly prostate cancers (Miki et al., 1994; Ford et al., 1994; Streuwing et al., 1997) . Various functional activities of BRCA1 ± including its ability to regulate progression through the cell cycle, apoptosis, DNA repair events, and the maintenance of genomic integrity ± may contribute to the biologic activity of this gene as a tumor suppressor (reviewed elsewhere (Chen et al., 1999) ). However, these so-called`caretaker' activities of BRCA1, some of which parallel the activities of the p53 tumor suppressor gene, do not appear to be cell-type speci®c. Thus, they do not, by themselves, fully elucidate the association of BRCA1 gene mutations with speci®c cancer types, such as breast cancer. The strong association of BRCA1 gene mutations with breast cancer development suggests that in addition to`generic' tumor suppressor activities, BRCA1 may also have a direct, mammary tissue-speci®c biologic function.
Over-expression of a wild-type BRCA1 gene (wtBRCA1) was recently found to inhibit signaling by the liganded estrogen receptor [ER-a] in various human breast and prostate cancer cell lines (Fan et al., 1999) . Speci®cally, wtBRCA1 blocked estrogen-stimulated ER-a mediated activation of an estrogen-responsive reporter (ERE-TK-Luc) through the estrogen-responsive enhancer element (ERE) and inhibited the liganddependent transcriptional activity of the conserved carboxyl-terminal activation domain AF-2 of ER-a. A role for chronic over-stimulation of mammary epithelium by estrogen has long been thought to be a key factor in the development of breast cancer; and current strategies for breast cancer prevention and treatment include the use of selective anti-estrogens (e.g., Tamoxifen and Raloxifene) (Chlebowski, 2000) .
We therefore postulated that the inhibition of estrogenic stimulation of mammary epithelial cell growth by BRCA1 may contribute to breast cancer suppression, and that the loss of this inhibitory activity may promote mammary carcinogenesis. Thus, the loss of the caretaker activities of BRCA1 due to mutational inactivation may be an early event leading to the accumulation of genetic damage; while the loss of the ability of BRCA1 to suppress ER-a transcriptional activity may contribute to the proliferation of genetically damaged mammary epithelial cells.
Thus, the role of the BRCA1 gene in breast cancer suppression is postulated to be twofold: (1) to maintain genomic integrity; and (2) to limit the extent of estrogenic stimulation of mammary epithelial cell proliferation by regulating the transcriptional activity of ER-a. To better understand the role of the BRCA1 gene in the pathogenesis of breast cancer, we have identi®ed one of the mechanisms by which BRCA1 may inhibit ER-a signaling: i.e., through a direct physical interaction between the BRCA1 and ER-a proteins.
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Results
Mutant BRCA1 genes are defective in the ability to inhibit ER-a transcriptional activity
We tested a panel of mutant BRCA1 genes, including tumor-associated and arti®cially engineered mutants (Figure 1a) , to assess the impact of mutations on the ability of BRCA1 to inhibit ER-a activity. Some of the BRCA1 proteins could be demonstrated by Western blotting: wtBRCA1, 5677insA, T300G, RXRXH (fulllength or near full-length proteins of about 220 kDa), and DKpn1 (87 kDa) (see Figure 1b) . Since the other BRCA1 mutant proteins are poorly detected by commercially available antibodies (particularly amino- terminal BRCA1 antibodies), the mRNA expression of the BRCA1 mutant genes was assessed by semiquantitative RT ± PCR analysis (Fan et al., 1998) . In order to identify the truncated BRCA1 mRNA species, three sets of primers mapping to widely separated sites in BRCA1 (see Figure 1a , bottom) were tested. Thus, comparisons of the relative amounts of the dierent ampli®ed cDNA segments with that of the controls (parental and pcDNA3 vector-transfected cells), by densitometry analysis, allowed us to detect increased mRNA expression corresponding to the truncated or mutant BRCA1 genes ( Figure 1c ).
As expected, primer #1 yielded increased levels of the 285-bp product in cells transfected with wtBRCA1, 5677insA, RXRXH, T300G, C5365G, and 5382insC; but mutations that truncate the BRCA1 mRNA 5' to the primer (D BamHI, D KpnI, D EcorI) failed to yield an increase in the 285-bp product, relative to untransfected or empty vector-transfected controls. Primer #2 yielded an increase in the 457-bp product in cells transfected with wtBRCA1, 5677insA, D BamHI, RXRXH, T300G, 5382insC, and C5365G, all of which yield mRNAs that include the ampli®ed cDNA segment. On the other hand, D Kpn1 and D EcoRI, which encode mRNAs truncated 5' to the primer, failed to yield an increase in the 457-bp product. Primer #3, which maps to the amino-terminus of BRCA1, gave increased 196-bp product in all but control transfections. The quantities of ampli®ed cDNA segments were increased about 3 ± 4-fold, indicating increased expression of the BRCA1 expression plasmids.
These ®ndings con®rm the expression of all BRCA1 mRNAs, except 185delAG, the expression of which was not dierent from the control cells. The 185delAG encoded mRNA appears to have a very short half-life. Because of the tiny size of the predicted protein product (only 38 aa), even if the 185delAG transgene were expressed, it would be unlikely to confer altered phenotypic characteristics. This frame-shift mutation probably behaves as a null mutation. Although not all of the carboxyl-terminally truncated BRCA1 proteins could be detected directly by Western blotting, we were able to detect the BRCA D BamHI, D Kpn1 and D EcoRI protein products when an amino-terminal epitope (FLAG) tag was added, indicating that these proteins are produced under assay conditions (see below).
We tested the ability of the BRCA1 cDNAs to inhibit estradiol (E2) induced, ER-a mediated ERE-TK-Luc reporter activation in DU-145 and T47D cells. Luciferase activity (relative to the -E2 negative control) was normalized for transfection eciency by cotransfection of the control plasmid pRSV-b-gal. wtBRCA1 and BRCA1-5677insA (Y1853term), which corresponds to a tumor-associated mutation that deletes 11 amino acids [aa] and ablates activity of the carboxyl-terminal transactivation domain [TAD] (Monteiro et al., 1996; Chapman and Verma, 1996) , abolished reporter activity (Figure 1d ). However, two other carboxyl-terminal tumor mutations, 5382insC (Q1756term) and C5365G (P1749R) (Miki et al., 1994; Streuwing et al., 1997) , failed to inhibit ER-a activity. These mutations also abolish the activity of the TAD (Monteiro et al., 1999) .
A tumor-associated mutation of the amino-terminal RING domain (T300G) and a mutation of the consensus retinoblastoma [Rb] binding motif LXCXE (RXRXH) abolished ER-a inhibitory activity in both cell lines (Figure 1d ). A second tumor-associated point mutation of the RING domain (T310G) also failed to suppress ER-a activity (data not shown). Examination of deletion mutants revealed that 185delAG, a tumorassociated mutation that truncates BRCA1 in the RING domain, and BRCA1 D EcoRI, which truncates (Fan et al., 1998) were tested. (b) Transient transfection of MCF-7 cells with wtBRCA1 suppressed E2-stimulated activation of the ERE-TK-Luc reporter by endogenous cellular ER-a. The inset shows the very high transfection eciency (495% of cells in pRSV-b-gal transfected cultures staining blue with X-gal) achieved when cells were transfected under similar conditions with an expression plasmid for b-galactosidase (pRSV-b-gal) (+) or the empty vector (7) (negative control) and stained using X-gal. (c) Wild-type BRCA1 inhibits the E2-stimulated expression of the endogenous pS2 and cathepsin D genes in breast cancer cells (MCF-7 (left) and T47D (center)] in the absence of exogenous ER-a. However, two tumor-associated mutant BRCA1 genes (5382insC and T300G) failed to inhibit the E2-stimulated pS2 expression in T47D cells (right panel). Cells were transfected overnight with wtBRCA1, mutant BRCA1, or empty pcDNA3 vector, washed, and incubated in serum-free DMEM (5.0 ml per 100 mm dish)+E2 (1 mM). Conditioned medium was concentrated 10-fold using a 3 kDa membrane; and 1/10 of the concentrate was used for Western blotting. (d) DU-145 cells expressing wtBRCA1 under the control of a TCN regulated promoter (DU-145/Tet-O/BRCA1) showed up-regulation of BRCA1 protein and inhibition of ER-a activity when TCN (2 mg/ml) was removed from the culture medium for 524 h. On the other hand, control (DU-145/Tet-O/Neo) cells failed to exhibit TCN-dependent inhibition of ER-a activity. (e) Estradiol-stimulated ER-a activity, as determined using the ERE-TK-Luc assay, was E2 dose-dependent, as illustrated using DU-145 cells. ERE-TK-Luc activity was signi®cantly inhibited by wtBRCA1 at all E2 doses tested Oncogene BRCA1: Estrogen receptor interaction S Fan et al BRCA1 just before LXCXE, failed to inhibit ER-a activity (Figure 1d ). Mutants that truncate BRCA1 after LXCXE but before the TAD (D Kpn1, D BamHI) yielded 50% inhibition in DU-145 and no inhibition in T47D. Since E2 typically induces reporter activity by 100 ± 1000-fold and wtBRCA1 reduces the activity to near baseline (onefold stimulation), a 50% reduction of activity is probably not meaningful.
Dierences in the degree of inhibition of ER-a activity by dierent BRCA1 genes could not be attributed to dierences in transfection eciency, since co-transfection of the control plasmid pRSV-b-gal yielded similar b-galactosidase activities for all transfections. These ®ndings suggest that inhibition of ER-a requires several functional domains, including the RING and LXCXE motifs, as well as another domain located carboxyl-terminal to the BamHI site (aa 1313).
Since the tumor-associated BRCA1 mutant 5677insA strongly suppressed ER-a activity at the single plasmid dose tested, we compared the relative ability of 5677insA vs wtBRCA1 to inhibit ER-a at a series of dierent plasmid doses. When tested side-by-side, the wtBRCA1 gene was about ®vefold more eective (mg/ mg) than the 5677insA gene at inhibiting ER-a transcriptional activity in both DU-145 and T47D cells, calculated based on the plasmid DNA doses required to produce 50% inhibition of ER-a activity (see Figure 1e ). These ®ndings suggest that the 5677insA mutation signi®cantly weakens the ability of BRCA1 to inhibit ER-a activity, although the 5677insA gene product retains the ability to inhibit ER-a activity when expressed at suciently elevated levels. Taken together, these results suggest that a site within the minimal TAD of BRCA1 (last 100 ± 120 aa) is required for the maximal inhibition of ER-a activity. Figure 4 wtBRCA1 suppresses ER-a activity and truncated BRCA1 proteins reverse the suppression in a breast cancer cell line (HCC1937) that lacks endogenous functional BRCA1. (a) Expression of full-length and truncated BRCA1 proteins containing an N-terminal FLAG epitope tag. Transient transfections were carried out as described above; and the cells were subjected to Western blotting using an anti-FLAG antibody. (b) Transient transfection ER-a transcriptional assays were carried out as described above, using FLAG-tagged BRCA1 expression vectors and HCC1937 human breast cancer cells, a cell line that contains a single mutant BRCA1 allele (5382insC)
While the results shown in Figure 1 are based on transient transfection assays, transient transfection of the BRCA1 gene into cells was not required to demonstrate suppression of ER-a activity. Thus, DU-145 cell clones stably transfected with the wtBRCA1 gene showed only a signi®cantly smaller amount of E2-stimulated, ER-a mediated activation of ERE-TK-Luc (ca. fourfold), as compared with while empty vector (neo) transfected control cell clones, which showed typically high (1000-fold) E2-stimulated ER-a activity (Figure 2a) . Transient transfection of MCF-7 breast cancer cells with wtBRCA1 suppressed E2-stimulated activation of the ERE-TK-Luc reporter by endogenous cellular ER-a (i.e., no transfected ER-a plasmid) (Figure 2b ). Co-transfection of a control plasmid (pRSV-b gal) showed that the transfection eciency was uniformly high (see Figure 2b, inset) .
Furthermore, the wtBRCA1 gene blocked the E2-stimulated expression of two endogenous E2-responsive genes (pS2 and cathepsin D) (Faust et al., 1985; Jeltsch et al., 1987) by endogenous ER-a (i.e., no transfected ER-a plasmid), in MCF-7 (Figure 2c , left) and T47D (Figure 2c , center). The E2 stimulation of pS2 expression and its inhibition by the wtBRCA1 gene was also observed at the mRNA level, by Northern blotting (data not shown). Consistent with the ERE-TK-Luc reporter experiments, two tumor-associated mutant BRCA1 genes, 5382insC and T300G, failed to suppress E2-stimulated endogenous pS2 expression in T47D cells, while wtBRCA1 strongly suppressed pS2 expression (Figure 2c, right) . DU-145 cells expressing wtBRCA1 under the control of a tetracycline [TCN] regulated promoter (DU-145/Tet-O/BRCA1) showed strong inhibition of ER-a activity when TCN was removed from the culture medium ( Figure  2d ). On the other hand, control (DU-145/Tet-O/Neo) cells failed to exhibit TCN-dependent inhibition of ER-a activity. Thus, either transient or stable expression of BRCA1 inhibits ER-a activity.
In the experiments described above, the E2 concentrations were very high (1 mM), to ensure a high level of stimulation of ER-a activity in the 7wtBRCA1 positive controls. However, we performed a dose-response experiment to determine if wtBRCA1 similarly suppressed E2-stimulated ERE-TK-Luc activity at physiologic (5100 nM) as well as supraphysiologic E2 concentrations. As illustrated in Figure 2e , E2 induced a dose-dependent stimulation of reporter activity in DU-145 cells that was signi®cantly inhibited by the wtBRCA1 gene at all E2 concentrations tested. At extremely high and unphysiologic E2 concentrations (5 and 10 mM), the degree of inhibition of ER-a activity by wtBRCA1 was somewhat less than at doses of E2 from 1 nM to 1 mM. Within the latter dose range, the residual ERE-TK-Luc activity in the presence of wtBRCA1 was close to the unstimulated (-E2) baseline value.
Association of the BRCA1 and ER-a proteins in vivo
To determine if a physical association of BRCA1 and ERa might contribute to suppression of ER-a activity, we tested an ER positive breast cancer cell line (MCF-7) by immunoprecipitation [IP]-Western blotting. ER-a was detected in the BRCA1 IP of MCF-7 cell nuclei and vice versa (Figure 3a) . Control IPs using non-immune antibodies failed to yield BRCA1 or ER-a protein bands. While BRCA1 was precipitated from DU-145 cells, there was little or no ER-a detected in the ER-a or BRCA1 IPs (Figure 3a) , consistent with the ER negative status of this cell line (Webber et al., 1997) . On the other hand, DU-145 cells transfected with wtBRCA1 (to enhance expression) and ER-a expression vectors showed association of BRCA1 and ER-a, in the presence or absence of E2 (Figure 3b ). These ®ndings indicate that BRCA1 and ERa associate within the same protein complex, independently of estrogen.
BRCA1 inhibits and truncated BRCA1 mutants rescue ER-a activity in cells lacking endogenous functional BRCA1
To determine if the activity of transfected wtBRCA1 is similar in cells lacking functional endogenous BRCA1, ER-a transcriptional assays were performed in human breast cancer cell line HCC1937, which has a single mutant BRCA1 allele (5382insC). Cells were transiently transfected with cDNAs encoding wild-type and/or truncated BRCA1 proteins expressed with an aminoterminal FLAG epitope tag, to allow detection and localization of the tagged proteins. FLAG Western blots con®rmed expression of BRCA1 proteins of the predicted sizes: Tag-wtBRCA1 (220 kDa), Tag-D EcoR1 (37 kDa), Tag-D Kpn1 (87 kDa), and Tag-D BamHI (147 kDa) (Figure 4a ). Immunostaining revealed that all of these proteins localized primarily to the nucleus (data not shown).
As observed in cells with functional BRCA1 (see below), wtBRCA1 but not truncated mutant BRCA1 genes strongly suppressed ER-a activity (Figure 4b ). However, each of the carboxyl-terminal truncated BRCA1 genes partially but strongly rescued the wtBRCA1 suppression of ER-a activity. As is documented below, each of these truncated BRCA1 proteins contains the amino-terminal ER-a binding site.
Interaction of BRCA1 and ER-a in vitro and mapping of the binding sites
To determine if the association of BRCA1 and ER-a is due to a direct physical interaction, we performed glutathione-S-transferase [GST] capture assays using in vitro translated [IVT] BRCA1 and beads coated with a series of GST-ER fusion proteins. Figure 5a shows schematic diagrams of the series of ER-a constructs tested; Figure 5b shows the various GST-ER fusion proteins visualized by Western blotting, using an anti-GST antibody. Among six GST-ER proteins tested, three carboxyl-terminal ERa peptides (ER 282 ± 420, ER 282 ± 595, ER 393 ± 595) captured IVT-wtBRCA1; while three more aminoterminal ER-a peptides (ER 1 ± 185, ER 1 ± 282, ER 282 ± 337) failed to capture wtBRCA1 (Figure 5c ).
To delineate the binding site(s) for ER-a on BRCA1, we tested various IVT BRCA1 proteins (see Figure 1a) for binding to GST-ER 282-420. An autoradiograph of the IVT BRCA1 translation products is shown in Figure  5d , which illustrates the relative translational eciency for the dierent products. All BRCA1 proteins tested bound to GST-ER 282-420, with the most binding for BRCA1D EcoRI (=aa 1 ± 302) (Figure 5e ). The ratio of bound : input BRCA1 was higher for carboxyl-terminal peptides than for full-length or near full-length BRCA1 proteins (Figure 5f ), suggesting interference to binding by a carboxyl-terminal portion of BRCA1, but this remains to be proven.
These ®ndings suggest that ER-a binds to a site in the amino-terminus (aa 1 ± 302) of BRCA1. Consistent with this hypothesis, a GST-ER 282-40 fusion protein captured full length wtBRCA1 (aa 1 ± 1863) but failed to capture either of two amino terminally truncated IVT BRCA1 proteins (BRCA1 772 ± 1863 or BRCA1 1314 ± 1863) (Figure 5g ). However, co-transfection of BRCA1 D EcoRI resulted in a dose-dependent rescue of the wtBRCA1-mediated inhibition of ER-a activity in DU-145 cells (Figure 5h ), which contain endogenous wildtype BRCA1 protein, suggesting that an amino-terminal fragment of BRCA1 (aa 1 ± 302) can function as a dominant inhibitor of the full-length wtBRCA1. These ®ndings suggest an E2-independent interaction of BRCA1 and ER-a involving aa 1 ± 302 of BRCA1 and the AF-2/ligand-binding domain [LBD] region of ER-a. The failure of the BRCA1 D EcoRI gene to inhibit ER-a activity (see Figure 1d) suggests that binding to ER-a is insucient for inhibition and that a more carboxyterminal domain of BRCA1 is also required.
Discussion
We showed that various mutant or truncated forms of BRCA1 are defective in their ability to suppress ER-a transcriptional activity. The failure of mutant forms of BRCA1 to inhibit ER-a activity may contribute to the development of breast cancer. This idea is consistent with the ®nding that eight out of nine mutant BRCA1 genes ± four tumor-associated mutations (5382insC, C5365G, T300G and 185delAG), a mutation of the consensus Rbbinding motif LXCXE (RXRXH), and three deletion mutants (D EcoRI, D KpnI, and D BamHI) ± showed little or no inhibitory activity. The 5382insC and 185delAG are commonly observed mutations, which occur in approximately 0.3% and 1% respectively, of Ashkenazi Jews (Streuwing et al., 1997) .
One rare tumor-associated mutant BRCA1 gene (5677insA) (Friedman et al., 1994) retained ER-a inhibitory activity at high plasmid doses, but exhibited signi®cantly weaker inhibitory activity than the wtBRCA1 gene at lower plasmid doses. The partial retention of ER-a inhibitory activity might explain the rarity of this and other mutations of exon 24 of BRCA1 in breast cancer families. Recent studies suggest that associated genetic factors may also contribute to the high incidence of breast cancer observed in BRCA1 kindreds (Streuwing et al., 1997) . The frequencies of ER negativity (Loman et al., 1998) and of chromosomal aberrations (particularly deletions) (Tirkonnen, 1997) are higher in BRCA1-related breast cancers than in sporadic breast cancers. These ®ndings suggest that other genetic alterations may allow estrogen-independent growth in the setting of a BRCA1 mutation that weakens but does not abrogate the ability to inhibit ER-a activity. In particular, our ®ndings suggest that regions within the amino-and carboxyl-termini of BRCAq are essential for inhibition of ER-a activity.
Breast cancer is a multi-step process. Thus, patients born with a BRCA1 gene mutation are exposed for many years to the interaction between the mutant BRCA1 protein and wild-type ER-a. The BRCA1 : ERa interaction must exist for many years in the mammary tissue of these patients. The loss of ER-a in some BRCA1-associated cancers (Loman et al., 1998 ) is likely to be a late event in the progression of the multi-step process of tumorigenesis.
Our ®ndings are consistent with a model in which the amino-terminal region of BRCA1 (approximately aa 1 ± 300) physically interacts with ER-a, and the carboxylterminus of BRCA1 acts as a transcriptional inhibition domain. BRCA1 was found to interact with the carboxylterminal activation domain AF-2 of ER-a, in agreement with the prior ®nding that BRCA1 speci®cally inhibits the AF-2 transcriptional activity (Fan et al., 1999) . Consistent with the proposed model, a transcriptional inhibitory function for the carboxyl-terminus of BRCA1 has been suggested by the ®ndings that this region of BRCA1 is capable of binding to components of repression complexes, including the Rb protein, Rbassociated proteins [RbAp46 and RbAp48], histone deacetylases [HDACs] , and the carboxyl-terminal interacting protein [CtIP] (Yu et al., 1998; Yarden and Brody, 1999) . CtIP can then recruit CtBP (carboxyl-terminal binding protein), a potent co-repressor thought to mediate transcriptional repression during development. Thus, BRCA1 may function as an inhibitory adapter ± ie., to recruit repressor proteins ER-a bound to EREs within the regulatory regions of estrogen-responsive genes ± although the details of this mechanistic pathway remain to be elucidated. This model is supported by the observation that several BRCA1 fragments containing the ER-a interact- ing domain but missing the carboxyl-terminal transcriptional regulatory region (eg., BRCA1 aa 1 ± 302, aa 1 ± 772, and aa 1 ± 1313) rescued the wtBRCA1-mediated suppression of ER-a activity. Although our BRCA1 antibodies do not detect the DEcoRI protein (aa 1 ± 302), we found that a FLAG-tagged BRCA1 D EcoRI protein with similar rescue ER-a activity is well expressed and localizes signi®cantly to the nucleus. Although the D EcoRI fragment lacks the canonical nuclear localization signal (aa 501 ± 508), this region of BRCA1 interacts with various other nuclear-localized proteins (eg., BARD1, cyclin D1, cyclin-dependent kinases, c-Myc, and even p300/CBP (see Chen et al., 1999; and see below) . Thus, the D EcoRI fragment might enter the nucleus`piggy backed' to another protein.
The ability of BRCA1 to suppress ER-a dependent activities was not limited to E2-dependent reporter assays. The wtBRCA1 gene also blocked the expression of two endogenous E2-responsive gene products (pS2 and cathepsin D) in ER positive, estrogen-responsive human breast cancer cell lines, MCF-7 and T47D. Furthermore, it was not necessary to transiently transfect the wtBRCA1 gene into cells to demonstrate suppression of ER-a activity. Human prostate cancer cell (DU-145) clones stably transfected with wtBRCA1 or with a wtBRCA1 cDNA under the control of a TCN-responsive promoter also showed strong inhibition of E2-stimulated, ER-a activity by BRCA1, as compared with the appropriate controls. Finally, a human breast cancer cell line (HCC1937) containing a single mutant BRCA1 allele (5382insC) and no endogenous wild-type BRCA1 also showed wtBRCA1-mediated inhibition of ER-a activity, in transient transfection assays. Since the 5382ins C gene failed to suppress ER-a activity and also failed to suppress E2-stimulated expression of the endogenous estrogenresponsive gene pS2, these ®ndings establish that the wildtype BRCA1 protein can suppress ER-a signaling in the absence of any endogenous functional BRCA1.
Nonetheless, it is noted that the experiments performed using the ER-a negative cell line DU-145 required the use of exogenous ER-a expression vector, introducing an additional arti®cial element into the assay system. Whether the arti®cial expression of ER-a contributed to the modest reduction of ER-a activity (50 ± 60% or so) in DU-145 cells caused by two truncated BRCA1 mutant proteins (D BamHI and D KpnI) is unclear; and it is also unclear whether these small reductions in activity are physiologically meaningful. However, similar reductions of ER-a activity were not observed in the estrogen-responsive breast cancer cell line T47D (see Figure 1d) . It is noted that in our previous study (Fan et al., 1999) , wtBRCA1 strongly inhibited ER-a activity in LNCaP, an estrogen-responsive human prostate cancer cell line with endogenous ER-a expression. Thus, it appears likely that the full-length wtBRCA1 protein inhibits ER-a activity in prostatic as well as mammary epithelial cells.
The mechanism by which the physical interaction between BRCA1 and ER-a results in suppression of ER-a activity is probably quite complex, since the BRCA1 suppression of ER-a activity can be partially or fully reversed by over-expression of one of several co-factors, including p300, its functional homolog CBP (the CREB binding protein), or cyclin D1 (manuscript submitted for publication). At this point, it is not absolutely clear whether reversal of the BRCA1 inhibition requires that BRCA1 be released from the ER-a transcriptional complex, or whether the presence of speci®c transcriptional co-factors within that complex can otherwise`neutralize' the inhibitory eects of the BRCA1 protein. It should also be recognized that other mechanisms besides a direct physical association of BRCA1 with the activation domain AF-2 could also contribute to the ability of BRCA1 to suppress ER-a activity, such as BRCA1-mediated alteration of ER-a DNA binding activity. Our studies do not rule out this and other possibilities.
In summary, our ®ndings suggest that BRCA1 functions to repress ER-a transcriptional activity through a mechanism that, at least in part, involves a physical interaction of the amino-terminus of BRCA1 with the activation domain (AF-2) of ER-a. BRCA1 repression of ER-a activity also requires the carboxyl terminus of BRCA1, which might function as a repression domain, and can be antagonized by truncated BRCA1 proteins missing the carboxyl terminus.
Materials and methods
Cell lines
All cell lines used in this study (DU-145, T47D, MCF-7, and HCC1937) were originally obtained from the American Type Culture Collection and cultured as described before (Fan et al., 1998) . The production and characterization of stable wtBRCA1-transfected DU-145 cell clones were described earlier (Fan et al., 1998) . DU-145 cell clones expressing the wtBRCA1 gene under the control of a tetracycline-regulated promoter were prepared using the Tet-O R system (Invitrogen).
Expression vectors and reporters. BRCA1
The wild-type BRCA1 expression plasmid (wtBRCA1) was created by cloning the BRCA1 cDNA into the pcDNA3 vector (Invitrogen) using arti®cially engineered 5' HindIII and 3' NotI sites. Mutant BRCA1 expression vectors were created by modi®cation of the BRCA1 cDNA in the pcDNA3 vector. BRCA1 mutants 5382insC and C5365G were a gift from Dr Barbara Weber (School of Medicine, University of Pennsylvania, Philadelphia, PA, USA). In some experiments, wild-type and mutant BRCA1 cDNAs were expressed in vector pCMVTag2 (Stratagene), which allows expression of the protein with an N-terminal FLAG sequence. The wild-type expression vector pCMV-ER-a (ER-a) was used to express ER-a.
Reporter
The estrogen-responsive reporter ERE-TK-Luc is composed of the vitellogenin A2 estrogen-responsive enhancer (ERE) controlling a minimal thymidine kinase promoter (TK81) and luciferase, in plasmid pGL2 (Henttu et al., 1998) .
RT ± PCR analysis
Semi-quantitative RT ± PCR assays were performed as described earlier (Fan et al., 1998) . The BRCA1 primer sequences BRCA1: Estrogen receptor interaction S Fan et al
